Organization (Industry)
VERTEX, INC.
ClinicalTrials.gov lists VERTEX, INC. as lead sponsor of 247 trials. It has 78 active development programs and 35 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 16 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 17 in 2026 and about 17 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 1 trial is registered to start in 2027 or later.
Logo Vertex Pharmaceuticals Company, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers VERTEX, INC.: 247 lead-sponsored trials and 5 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (50)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Cystic Fibrosis | 132 |
| Hepatitis C | 46 |
| Pain | 39 |
| Hepatitis C, Chronic | 21 |
| Acute Pain | 11 |
Showing 5 of 50 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 16 |
| 2025 | 16 |
| 2024 | 22 |
| 2023 | 16 |
| 2022 | 25 |
| 2021 | 11 |
| 2020 | 10 |
| 2019 | 10 |
| 2018 | 16 |
| 2017 | 15 |
Showing 10 of 24 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 27 trials still running at the 2026-10-09 snapshot; registered median of 12 months across 202 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (78)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| CTX001 | Anemia | Phase 3 | 5 |
| IVA | Cystic Fibrosis | Phase 3 | 46 |
| CTX001 | beta-Thalassemia | Phase 3 | 4 |
| CTX001 | Thalassemia | Phase 3 | 4 |
| CTX001 | Anemia, Sickle Cell | Phase 3 | 3 |
Showing 5 of 78 active programs.
Approved assets (35)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Suzetrigine | 24 |
| Telaprevir | 19 |
| Ribavirin | 19 |
| PEGinterferon alfa-2a | 15 |
| LUM/IVA | 8 |
Showing 5 of 35 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 72% hit target (n=111) | 65% on time (n=106) |
Journals published in (72)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 21 |
| Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 19 |
| The Lancet. Respiratory medicine | 18 |
| American journal of respiratory and critical care medicine | 12 |
| Annals of the American Thoracic Society | 4 |
Showing 5 of 72 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,208 | 128 | 2025-12-30 |
SEC-reported annual financials (9)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 748,444,000 | 7,211,000 | 83,715,000 |
| 2024 | 666,776,000 | -52,729,000 | 66,666,000 |
| 2023 | 572,387,000 | -13,093,000 | 58,212,000 |
| 2022 | 491,624,000 | -12,304,000 | 41,877,000 |
| 2021 | 425,548,000 | -1,479,000 | 44,018,000 |
| 2020 | 374,665,000 | -75,081,000 | 54,340,000 |
| 2019 | 321,500,000 | 31,057,000 | 30,557,000 |
| 2018 | 272,403,000 | -6,106,000 | 23,755,000 |
| 2017 | not reported | not reported | not reported |
Financing and grant events (17)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-11-14 | Debt financing | not disclosed | Sec extracted |
| 2025-10-30 | Other financing | not disclosed | Sec extracted |
| 2024-11-04 | Debt financing | not disclosed | Sec extracted |
| 2024-08-06 | Private placement | not disclosed | Sec extracted |
| 2024-04-26 | Debt financing | 333,700,000 | Sec extracted |
Showing 5 of 17 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 13 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2021-12-07 |
Manufacturing and distribution sites (3)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | Boston, US | FDA, Health Canada | |
| VERTEX PHARMACEUTICALS INCORPORATED | BOSTON, US | EMA, Health Canada | |
| Vertex Pharmaceutical Incorporated | Boston, US | Health Canada |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (31)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Cystic Fibrosis Foundation | Co sponsors trial with | 14 |
| Parion Sciences (United States) | Co sponsors trial with | 3 |
| Children's Hospital of Philadelphia | Co sponsors trial with | 3 |
| Université de Montréal | Co sponsors trial with | 2 |
| Nottingham University Hospitals NHS Trust | Co sponsors trial with | 2 |
Showing 5 of 31 relationships.
Latest dated events (1,527)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-07-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 1,527 events.
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| VERTEX PHARMACEUTICALS | Certificate of waiver | Active |
| VERTEX LLC | Certificate of waiver | Terminated |
| VERTEX LLC | Certificate of waiver | Terminated |
Biomarker capability evidence (443)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AFP | Trial collaborator | Named in trial inclusion criteria |
| AFP | Trial collaborator | Named in trial inclusion criteria |
| AFP | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 443 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, fda warning letters, fda untitled letters, fda recalls, and biomarkers this organization publishes on.